why choose us

First received: September 15, 2023

Clinical Trial: Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers

Study Status: Completed

Recruit Status: RECRUITING

Condition: Biliary Tract Carcinoma

Study Type: INTERVENTIONAL


Official Title: Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) During First Line Treatment of Advanced Biliary Tract Cancers (BTC).

Brief Summary: This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC).The study will include a safety run-in involving 6 study participants.The goal of the safety run-in is to screen for early safety signals of the proposed drug combination.Trial enrollment can continue while full safety assessment is being completed for the first 6 subjects.Participants will receive 4 cycles of combination therapy as described.After 4…

Read more